JAK1 and rheumatoid arthritis: Upadacitinib, a selective JAK1/3 inhibitor for the treatment of severe RA, inhibits IL‐6, GM‐CSF, and IFN‐γ production and has anti‐inflammatory potential for COVID‐19, and currently has one clinical trial registration (NCT04393311).276, 277